MabionCD20

About Mabion

Mabion S.A. is a European public CDMO specializing in the development and manufacturing of biologic drugs, with a core history in antibodies and biosimilars. The company is executing a strategic transformation to become a specialized, value-adding partner, evidenced by a growing client roster, strategic alliances (e.g., with Sartorius), and a focus on complex modalities like Antibody-Drug Conjugates (ADCs). While navigating financial stabilization, its goals include reaching break-even by end of 2026, supported by new financing and an expanded international business development team.

Therapeutic Areas